. >>> the relief, finally had positive action today, but we all know with the battles over the debt ceiling, we could be looking at some very difficult moments over the next couple of months. and that's why all week we've been focusing on the noneconomic big jpmorgan health care conference that started on monday, where biotech and pharma countries strut their stuff. acor, this is a small billion dollar biopharma firm focused on neurology. back in 2010, accorda received approval for a drug called empira that helps people with multiple sclerosis gain their ability to walk. talk about how horrible this disease is, but it is also a lucrative disease for those who are trying to combat it, why? because it's a lifelong chronic condition. at this point, though, acorda has gotten all the low-hanging fruit. the really impressive thing about this story is they could have multiple indications. that's the holy grail of the drug business. right now acorda is conducting phase two studies seeing if it can work on people with cerebral palsy and chronic strokes. half of them have mobility issues. these addit